Status:

COMPLETED

Antidepressant Safety in Kids Study

Lead Sponsor:

Duke University

Collaborating Sponsors:

National Institute of Mental Health (NIMH)

Conditions:

Anxiety Disorders

Depressive Disorders

Eligibility:

All Genders

7-17 years

Brief Summary

This study will evaluate the risks and benefits of treatment with a selective serotonin reuptake inhibitor or serotonin-norepinephrine reuptake inhibitor in children and adolescents with a pre-specifi...

Detailed Description

The Antidepressant Safety in Kids (ASK) study is part of the Child and Adolescent Psychiatry Trials Network (CAPTN). Selective serotonin reuptake inhibitor (SSRI) and serotonin-norepinephrine reuptak...

Eligibility Criteria

Inclusion

  • Receiving treatment in an outpatient, residential, or in-patient setting
  • Meets DSM-IV diagnostic criteria for at least one of the following disorders: anxiety disorder, depressive disorder, eating disorder, or obsessive-compulsive disorder
  • English- or Spanish-speaking

Exclusion

  • Inpatient status IF the enrolling inpatient clinician will not continue to follow the patient for the duration of the study
  • Sibling that is already enrolled in the study
  • Imminently suicidal and unable to comply with a no-suicide contract or, in the opinion of the treating clinician, has inadequate family monitoring for suicidality
  • Acutely psychotic at study entry
  • A demonstrated lack of benefit from or intolerance to SSRI/SNRI antidepressants, as a class
  • Receiving treatment with a tricyclic antidepressant (TCA) at study enrollment, with the exception of low doses for enuresis for chronic pain. Patients may receive adjunctive TCA treatment during the study at the clinician's discretion.
  • Received a monoamine oxidase inhibitor (MAOI), such as isocarboxazid (Marplan), phenelzine (Nardil), or tranylcypromine (Parnate), within the past 30 days
  • Parasuicidal behavior or milder forms of suicidality or activation that do not meet the diagnostic criteria
  • Refusal to participate in the pharmacogenomic study
  • For bipolar depressed patients, a mixed- or manic-state at study entry without stable treatment with a mood stabilizer for manic symptoms
  • Patient or family is unable to comply with the protocol

Key Trial Info

Start Date :

May 1 2007

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

July 1 2009

Estimated Enrollment :

569 Patients enrolled

Trial Details

Trial ID

NCT00395213

Start Date

May 1 2007

End Date

July 1 2009

Last Update

April 17 2015

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Child and Adolescent Psychiatry Trials Network (CAPTN)

Durham, North Carolina, United States, 27715